Aisling Capital believes the next decade will be marked by a revolution in healthcare driven by new therapeutics generated by biotechnology. The completion of the human genome has given scientists new insights into the causes of human disease. These insights, combined with the past 20 years of developments in the biotechnology industry, are leading to rapid expansion of novel approaches toward the diagnosis, prevention, and treatment of life-threatening illnesses. These advances have led to an ever-increasing demand for capital to complete the development and commercialization of new therapeutics. Our goal is to support the leading global healthcare companies that are building on these technical and medical breakthroughs to commercialize new healthcare products.

Monte Rosa Therapeutics

Elevation Oncology

Intercept Pharmaceuticals

Nuvation Bio

Poseida Therapeutics

Reneo Pharmaceuticals

Biohaven Pharmaceutical

Biomea Fusion

BridgeBio

Bristol-Myers Squibb

Syros Pharmaceuticals

T2 Biosystems

Talaris Therapeutics

Asensus Surgical

Verona Pharma

ViewRay

Aclaris Therapeutics

ADMA Biologics

Arcus Biosciences

Atreca

Avrobio

Aisling Capital

IPhone / Mobile Compatible

Viewport Meta

SSL by Default

Google Maps

WordPress

nginx

reCAPTCHA

AJAX Libraries API

reCAPTCHA v2

Founder and Senior Advisor

Dennis Purcell

Compliance Manager and Head of HR

Carol Zikopoulos

Controller

Hannah Wieder, CPA

Director of Investor Relations & Marketing

Jan Hoerrner

Director of Investor Relations and Marketing

PSBFStaff Hoerrner

Robert Wenzel

A. Controller

Ground Transportation Manager

Rich Soskis

No Title

Andrew Schiff

President and Chief Executive Officer

Brian Crowe

Steven A. Elms

Managing Partner

Stacey Seltzer​

Partner

Founder & Senior Advisor

Scott Braunstein

Operating Partner

Aftab Kherani

Eric Aguiar

Nuvation Bio is a global biopharmaceutical company focusing on unmet needs in oncology.

Biomea Fusion is a precision oncology company developing novel small molecules that target aggressive forms of cancer.

Bicara Therapeutics develops dual-action cancer therapies, combining targeted treatments with tumor modulators for enhanced impact.

Compass Pathways is a mental health care company that focuses on developing therapies for treatment-resistant depression.

Poseida Therapeutics is a biopharmaceutical company utilizing gene engineering capabilities to develop targeted therapeutics.

Forge Biologics is a gene therapy development engine, enabling access to life changing gene therapy programs.

Reneo Pharmaceuticals is an operator of a pharmaceutical company used to develop therapies for patients with orphan metabolic diseases.

Monte Rosa Therapeutics is a biotechnology company that develops cancer therapeutics that modulate protein degradation pathways.

Elevation Oncology is a clinical-stage biopharmaceutical company focused on the development of precision medicines for patients.

VYNE Therapeutics is a clinical late-stage biopharmaceutical company developing treatments associated with dermatologic conditions.

Post IPO Investors with Investments in Switzerland

Investors Active in Rhode Island

Debt Investors with Investments in West Coast

Late Stage Venture Investors with Investments in Kentucky

Aisling Capital New Fund

Aisling Capital IV

Fund III

New York

United States

North America

The Week’s 10 Biggest Funding Rounds: TeraWatt Electrifies With Huge Round, Biotech Wins Big

United Kingdom

Europe

Philippines

Asia

South Africa

Africa

India

HTML5

Modernizr

Google Analytics

Adobe Fonts

jQuery

F5 NGINX

Amazon EC2

GoDaddy

Wordpress

OrbiMed is a private equity firm specializing in healthcare investments, including biotechnology.

OrbiMed

RA Capital Investments is a private investment firm focusing on investments in healthcare and life sciences.

RA Capital Investments

HealthCare Royalty Partners is a global healthcare investment firm providing structured financing solutions to healthcare companies.

HealthCare Royalty Partners

Adit Ventures is a venture capital firm that invests in early-stage and growth-stage companies across various industries, including healthcare.

Adit Ventures

Great Wave Ventures is a venture capital firm that focuses on early-stage investments in technology and healthcare companies.

Great Wave Ventures

Blue Owl Capital is an investment management firm that invests across various asset classes, including healthcare and life sciences.

Blue Owl Capital

Aisling Capital is a private equity firm that specializes in growth equity investments in the healthcare sector. The firm focuses on providing capital to commercial-stage companies with a track record of revenue generation. Aisling Capital partners with management teams to help drive value creation through strategic guidance and operational support.

news_impact_assignment_basic

key_people

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

merger_acquisitions

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general	Nov 19, 2024 1:31 PM	49a03e87
public peers	general	May 13, 2024 6:07 PM	475b5fc0
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	Nov 19, 2024 8:07 AM	4c6c84ab
company summary	general
signals	general
crunchbase trigger	general	Oct 28, 2024 1:50 PM	9a0c7ea0
crunchbase profile	general	Oct 28, 2024 2:44 PM	c226b8e6
li profile	general	May 13, 2024 6:07 PM	c4c38433
translate crunchbase fundingrounds	general	Nov 6, 2024 3:12 PM	720b66cc
peers	general
news basic	general
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

COM:AISLINGCAPITAL

Aisling Capital